Meredith S. Pelster

Oncology

335 24th Ave N
Ste 200
Nashville, TN 37203

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer.

Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer.

Journal: The New England journal of medicine

Published: May 06, 2026

Sirexatamab in Combination with Bevacizumab and Chemotherapy as Second-Line Therapy for Advanced Colorectal Adenocarcinoma: the Phase II DeFianCe Trial.

Sirexatamab in Combination with Bevacizumab and Chemotherapy as Second-Line Therapy for Advanced Colorectal Adenocarcinoma: the Phase II DeFianCe Trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: April 23, 2026

Setidegrasib in Advanced Non-Small-Cell Lung Cancer and Pancreatic Cancer.

Setidegrasib in Advanced Non-Small-Cell Lung Cancer and Pancreatic Cancer.

Journal: The New England journal of medicine

Published: March 25, 2026

Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer.

Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer.

Journal: Nature medicine

Published: November 25, 2025

A randomized phase II trial of gemcitabine, nab-paclitaxel, cisplatin with or without a medically supervised ketogenic diet for patients with metastatic pancreatic cancer.

A randomized phase II trial of gemcitabine, nab-paclitaxel, cisplatin with or without a medically supervised ketogenic diet for patients with metastatic pancreatic cancer.

Journal: Cancer

Published: September 10, 2025

Domvanalimab and zimberelimab in advanced gastric, gastroesophageal junction or esophageal cancer: a phase 2 trial.

Domvanalimab and zimberelimab in advanced gastric, gastroesophageal junction or esophageal cancer: a phase 2 trial.

Journal: Nature medicine

Published: August 22, 2025

Tinengotinib for adults with advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 trial.

Tinengotinib for adults with advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 trial.

Journal: The lancet. Gastroenterology & hepatology

Published: May 10, 2025

Phase 1 study of zavondemstat (TACH101), a first-in-class KDM4 inhibitor, in patients with advanced solid tumors.

Phase 1 study of zavondemstat (TACH101), a first-in-class KDM4 inhibitor, in patients with advanced solid tumors.

Journal: The oncologist

Published: February 28, 2025

Integrated analysis of molecular and clinical features associated with overall survival in melanoma patients with brain metastasis.

Integrated analysis of molecular and clinical features associated with overall survival in melanoma patients with brain metastasis.

Journal: Acta neuropathologica communications

Published: November 24, 2024

Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer.

Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer.

Journal: Cancer discovery

Published: February 22, 2024

Adagrasib in Advanced Solid Tumors Harboring a KRASG12C Mutation.

Adagrasib in Advanced Solid Tumors Harboring a KRASG12C Mutation.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: April 26, 2023

Post-therapy emergence of an NBN reversion mutation in a patient with pancreatic acinar cell carcinoma.

Post-therapy emergence of an NBN reversion mutation in a patient with pancreatic acinar cell carcinoma.

Journal: NPJ precision oncology

Published: March 06, 2023

Showing 1-12 of 17

Last Updated: 09/26/2026